Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd

₹ 1,220 -0.87%
24 Jun - close price
About

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]

Key Points

Leadership[1]

<h1>14th largest and fastest growing in the Indian market</h1> <h1>15th largest generic company by prescriptions filled in the USA</h1> <h1>5th largest Indian generic co. in Europe.</h1>
  • Market Cap 34,423 Cr.
  • Current Price 1,220
  • High / Low 1,264 / 645
  • Stock P/E 24.2
  • Book Value 814
  • Dividend Yield 0.20 %
  • ROCE 9.86 %
  • ROE 6.98 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company's working capital requirements have reduced from 62.8 days to 43.8 days

Cons

  • The company has delivered a poor sales growth of 4.59% over past five years.
  • Company has a low return on equity of 8.68% over last 3 years.
  • Earnings include an other income of Rs.6,238 Cr.
  • Dividend payout has been low at 3.58% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
1,850 2,142 2,181 2,033 1,786 1,912 2,208 2,161 1,939 2,144 2,233 1,365 2,148
1,494 1,585 1,721 1,523 1,624 1,478 1,826 1,723 1,721 1,659 1,790 1,549 1,651
Operating Profit 356 557 460 510 162 434 382 439 218 485 443 -184 497
OPM % 19% 26% 21% 25% 9% 23% 17% 20% 11% 23% 20% -14% 23%
117 138 511 217 179 347 317 252 -425 18 54 234 5,933
Interest 63 59 53 50 74 40 52 56 59 62 58 74 83
Depreciation 37 37 40 41 42 45 46 46 47 49 50 51 52
Profit before tax 373 598 878 637 225 696 601 589 -313 392 389 -76 6,295
Tax % 8% 18% 14% 14% 9% 29% 30% 27% 56% 31% 22% 73% 27%
342 489 754 549 206 493 423 430 -137 272 302 -20 4,614
EPS in Rs 12.11 17.34 26.73 19.44 7.29 17.46 15.00 15.26 -4.87 9.63 10.72 -0.72 163.50
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1,949 2,301 5,086 6,115 7,989 5,520 6,305 6,713 7,568 8,142 8,221 7,891
1,617 1,805 3,618 4,349 5,089 4,417 4,977 5,407 5,676 6,453 6,748 6,649
Operating Profit 332 496 1,467 1,766 2,900 1,103 1,328 1,305 1,892 1,689 1,473 1,242
OPM % 17% 22% 29% 29% 36% 20% 21% 19% 25% 21% 18% 16%
116 67 -86 116 -89 326 954 624 469 1,044 490 6,238
Interest 44 31 30 36 153 191 224 256 266 236 207 277
Depreciation 25 30 119 100 105 96 106 139 151 160 184 202
Profit before tax 380 502 1,232 1,747 2,553 1,143 1,952 1,535 1,944 2,337 1,572 7,001
Tax % -2% 14% 18% 15% 16% 11% 17% 12% 15% 15% 23% 26%
386 434 1,008 1,484 2,141 1,014 1,622 1,355 1,649 1,998 1,209 5,167
EPS in Rs 14.25 15.99 37.14 52.60 75.86 35.95 57.49 48.01 58.46 70.80 42.84 183.12
Dividend Payout % 14% 12% 5% 4% 3% 6% 3% 5% 4% 4% 6% 1%
Compounded Sales Growth
10 Years: 13%
5 Years: 5%
3 Years: 1%
TTM: -4%
Compounded Profit Growth
10 Years: 13%
5 Years: 1%
3 Years: -4%
TTM: -10%
Stock Price CAGR
10 Years: 8%
5 Years: 22%
3 Years: 24%
1 Year: 89%
Return on Equity
10 Years: 12%
5 Years: 9%
3 Years: 9%
Last Year: 7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 27 27 27 28 28 28 28 28 28 28 28 28
Reserves 2,496 2,879 4,925 7,338 9,408 10,363 11,914 13,198 14,781 16,710 17,849 22,942
581 353 410 787 2,777 2,981 3,134 3,574 3,704 3,738 3,221 707
782 970 2,289 1,960 1,787 1,892 2,066 2,152 2,104 2,438 3,487 3,736
Total Liabilities 3,886 4,230 7,651 10,113 14,001 15,265 17,143 18,952 20,618 22,914 24,586 27,414
276 449 1,231 1,438 1,596 1,699 1,413 1,612 1,722 1,752 1,746 1,778
CWIP 172 83 294 276 271 420 286 200 131 109 172 176
Investments 1,294 1,409 1,660 1,858 1,867 3,213 3,269 4,714 6,990 8,559 10,334 12,965
2,143 2,289 4,466 6,541 10,267 9,933 12,174 12,426 11,774 12,494 12,334 12,496
Total Assets 3,886 4,230 7,651 10,113 14,001 15,265 17,143 18,952 20,618 22,914 24,586 27,414

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
253 114 145 355 878 1,124 2,490 1,579 1,243 1,216 1,474 -495
-119 211 -176 -1,545 -2,580 -1,137 -2,256 -1,607 -1,235 -897 -432 3,197
-14 -385 -32 1,223 1,879 -62 -155 -139 -81 -305 -978 -2,666
Net Cash Flow 120 -60 -64 32 177 -75 79 -168 -73 14 64 35

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 104 180 175 182 177 253 121 100 120 120 111 115
Inventory Days 128 126 161 182 172 195 141 115 94 100 117 130
Days Payable 287 337 343 306 221 273 258 217 201 205 225 307
Cash Conversion Cycle -55 -31 -6 59 129 175 4 -3 14 16 3 -62
Working Capital Days -2 98 104 155 179 252 168 130 141 92 52 44
ROCE % 15% 17% 33% 26% 29% 10% 13% 11% 12% 11% 11%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
46.63% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65%
26.82% 25.93% 24.18% 24.12% 24.23% 23.14% 23.19% 22.47% 25.51% 24.79% 23.71% 21.38%
9.73% 9.03% 10.86% 10.96% 10.50% 10.90% 10.69% 10.40% 9.10% 10.31% 10.92% 13.36%
0.00% 0.00% 0.00% 0.00% 0.00% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04%
16.82% 18.40% 18.31% 18.27% 18.63% 19.27% 19.45% 20.46% 18.70% 18.21% 18.70% 18.58%
No. of Shareholders 2,75,8013,29,8703,17,3833,10,5163,12,4733,13,5403,00,1062,85,4612,36,9082,32,6852,09,9311,99,451

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls